CompletedNCT00706654
Long-acting aripiprazole injections to prevent schizophrenia relapse
About this title
Read the official source — NCT00706654Medication studyAges 18–60Multiple countries
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
- Listed locations
- Cerritos and 97 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateStarted: September 1, 2008
- Recruitment status
- Completed
- Enrollment listed in the registry
- 937
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Belgium, ...
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT00706654
- Official title
Show the full official title
A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Schizophrenia
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cerritos, United States · Escondido, United States · Garden Grove, United States
76 more locations
- Oceanside, United States
- Orange, United States
- Pasadena, United States
- Pico Rivera, United States
- San Diego, United States
- Torrance, United States
- Washington D.C., United States
- Gainesville, United States
- Kissimmee, United States
- Plantation, United States
- Tampa, United States
- Chicago, United States
- Oak Brook, United States
- Shreveport, United States
- Towson, United States
- Kansas City, United States
- Buffalo, United States
- New York, United States
- Rochester, United States
- Hickory, United States
- South Carolina, United States
- Garfield Heights, United States
- Toledo, United States
- Oklahoma City, United States
- Charleston, United States
- Johnson City, United States
- Nashville, United States
- Arlington, United States
- Austin, United States
- Richmond, United States
- Milwaukee, United States
- Innsbruck, Austria
- Bruges, Belgium
- Burgas, Bulgaria
- Pazardzhik, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Santiago, Chile
- Temuco, Chile
- Valdivia, Chile
- Zagreb, Croatia
- Jämejala, Estonia
- Meegomäe, Estonia
- Tallinn, Estonia
- Tartu, Estonia
- Bully-les-Mines, France
- Élancourt, France
- Rennes, France
- Saint-Nazaire, France
- Baja, Hungary
- Balassagyarmat, Hungary
- Cegléd, Hungary
- Győőor, Hungary
- Milan, Italy
- Pisa, Italy
- Bełchatów, Poland
- Bialystok, Poland
- Bydgoszcz, Poland
- Choroszcz, Poland
- Krakow, Poland
- Leszno, Poland
- Pruszków, Poland
- Sosnowiec, Poland
- Wroclaw, Poland
- San Juan, Puerto Rico
- Pretoria, South Africa
- Cape Town, South Africa
- Busan, South Korea
- Daejeon, South Korea
- Gwangju, South Korea
- Incheon, South Korea
- Seoul, South Korea
- Muang, Thailand
- Bangkok, Thailand
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot and Placebo tablets.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia